Spots Global Cancer Trial Database for An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Official Title: An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Small Cell Lung Cancer
Study ID: NCT06179069
Conditions
Interventions
Study Description
Brief Summary: An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Detailed Description: This is an open-label, ascending, multiple-dose, phase 1 study of ZL-1310 administered intravenously (IV) every 3 weeks in subjects with relapsed/refractory (r/r) metastatic SCLC who have progressed after at least one platinum-based chemotherapy regimen.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zai Lab Site 2005, Duarte, California, United States
Zai Lab Site 2026, Sarasota, Florida, United States
Zai Lab Site 2013, Detroit, Michigan, United States
Zai Lab Site 2001, Hackensack, New Jersey, United States
Zai Lab Site 2002, Buffalo, New York, United States
Zai Lab Site 2018, Durham, North Carolina, United States
Zai Lab Site 2024, Cleveland, Ohio, United States
Zai Lab Site 2012, Charleston, South Carolina, United States
Zai Lab Site 2006, Fairfax, Virginia, United States
Zai Lab Site 2008, Falls Church, Virginia, United States
Zai Lab Site 1005, Bejing, Bejing, China
Zai Lab Site 1001, Guangzhou, Guangdong, China
Zai Lab 1002, Wuhan, Hubei, China
Zai Lab Site 1003, Nanchang, Jiangxi, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
